C2N at AAIC 2025 in Toronto
C2N Diagnostics, a pioneer in advanced brain health diagnostics, is adding to its evidence-based legacy at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto, Canada July 26 – 31. Please visit our C2N booth #1328.
C2N recently announced its new assays designed to measure core pathologies of Alzheimer’s disease within the blood – C2N eMTBR-tau243 and C2N %p-tau MAA. We encourage you to click this link to schedule a meeting with our team to talk with us about these important new assays to support your latest clinical research studies.
This year’s AAIC will feature C2N test data in 9 sessions and 23 posters. All sessions are held at the Metro Toronto Convention Centre, unless noted otherwise.
Highlights of Sessions by C2N Executives
Dr. Philip Verghese, SVP of Research and Development, C2N, will speak on:
Saturday, July 26
11:30 – 12:30
PIA Day Panel Session on:
Building Capacity to Conduct AD Clinical Trials in Low Resource Settings
Pier 7&8 - The Westin Harbour Castle
Tuesday, July 29
14:21 – 14:38
Cerebrospinal fluid eMTBR-tau243 tau correlates with [18F] GTP1 tau PET and the two biomarkers show similar correlations with clinical measures
Room 701
Hear Dr. Joel Braunstein, CEO of C2N, speak at:
C2N Product Theater Presentation
Wednesday, July 30
12:10 – 12:50
The Power of Precision Diagnostics to Address Clinical Dilemmas Across the AD Continuum
Exhibit Hall – Stage #2
C2N Poster
Sunday, July 27
Sunday 799
The Economic Utility of an Alzheimer’s Disease Blood Biomarker Test in the Evaluation of Cognitively Impaired Patients
Spotlight Talk on Blood Biomarkers
Monday, July 28
16:39 – 16:51
Determining eligibility for anti-amyloid treatments using blood biomarkers
Dr. Suzanne Schindler, Washington University St. Louis, MO
Presentations
All presentation times and locations are subject to change. Please refer to the final AAIC 2025 program in case of any changes.
Sunday, July 27
17:00 – 17:10
Clinical usefulness of plasma p-tau217 and eMTBR-tau243 combination for diagnosis and patient stratification*
Location: 701
Monday, July 28
14:50 – 15:00
Biological staging of Alzheimer’s disease with the novel plasma eMTBR-tau243 and %p-tau217*
Location: 2-27-FRS-A
16:15 – 16:27
Predicting onset of Alzheimer disease symptoms with a plasma %p-tau217 clock
Location: 105
16:27 – 16:39
Clinical performance of blood biomarkers across settings and countries
Location: Hall F
16:27 – 16:39
Trajectories of CSF and plasma MTBR-tau 243 and phosphorylated-tau species across the Alzheimer’s disease continuum*
Location: 105
16:39 – 16:51
Determining eligibility for anti-amyloid treatments using blood biomarkers
Location: Hall F
Tuesday, July 29
14:21 – 14:28
Cerebrospinal fluid MTBR243 tau correlates with [18F] GTP1 Tau PET and the two biomarkers show similar correlations with clinical measures
Location: 701
14:28 – 14:35
Variations in Plasma p-tau217 by Sociodemographic Factors Across World Regions in a Preclinical AD Clinical Trials Program: the AHEAD 3-45 Study
Location: 701
Wednesday, July 30
14:24 – 14:36
Biomarker development for the tau therapeutic landscape
Location: 718
*Work done at Dr. Bateman Lab, Washington University, St. Louis
Posters
All posters are displayed in the Exhibit Hall
Saturday, July 26
AIC-171
Interpreting positive plasma Aβ42/40 results when amyloid PET is negative*
Sunday, July 27
Sunday-250
Trajectories of plasma biomarker levels and Amyloid Burden in Alzheimer's disease: A Longitudinal ADNI Study
Sunday-252
Detecting and monitoring longitudinal pathological and clinical changes of Alzheimer's disease using plasma p-Tau217
Sunday-319
Rates of Alzheimer’s disease biomarker positivity stratified by sex and race in a specialty memory clinic
Sunday-329
APOE Genotype Modulates the Relationship Between Plasma P-tau217 and Amyloid Burden in Alzheimer's Disease
Sunday-349
Age of plasma Aβ42/40 positivity in Black and White individuals
Sunday-352
Plasma Alzheimer's Disease Biomarker Associations with eGFR in Black and White Older Adults
Sunday-502
The associations between major depressive disorder, plasma biomarkers of Alzheimer's disease, and mild behavior impairment among older adults
Sunday-563
A self-administered digital cognitive test together with a blood test accurately detect clinical Alzheimer's disease in primary care
Sunday-799
The Economic Utility of an Alzheimer’s Disease Blood Biomarker Test in the Evaluation of Cognitively Impaired Patients
Monday, July 28
Monday-023
Plasma Biomarker Characterization of Alzheimer’s Disease Psychosis in Study ACP-204-006
Monday-218
Association of Plasma Biomarkers of Alzheimer’s Disease with Incident Tau PET Positivity
Monday-232
Cognitive Performance and Biomarker Profiles in Puipui Malu Manatu (Preserving Memory) - a Population-Based Prevalence Study ADRD in American Samoa
Monday-240
Plasma Alzheimer's mass spectrometry biomarkers associated with cerebrospinal fluid dynamics
Monday-267
Blood-based biomarkers enrich for amyloid positive participants, reducing patient burden in PROGRESS-AD, a phase 2 clinical trial for early Alzheimer’s disease
AIC-299
Biological staging of Alzheimer’s disease with the novel plasma eMTBR-tau243 and %p-tau217*
Tuesday, July 29
Tuesday-222
Early Alzheimer's disease diagnosis and blood biomarkers: primary care physician attitudes, perceptions and barriers in the USA
Wednesday, July 30
Tuesday-261
Comparison of the Effect of Chronic Kidney Disease on Plasma p-tau217 Determinations versus %p-tau217 and the p-tau217/Aβ42 Ratio in an Amyloid Negative Cohort
Wednesday-285
Cognitive and Plasma Biomarker Profiles of Older Adults with Probable Alzheimer's Disease in Kinshasa, Democratic Republic of Congo
Wednesday-306
Investigating Salivary Extracellular Vesicles as Biomarkers for Alzheimer's Disease: ExosomeAD Study Design and Baseline Characteristics
Wednesday-326
Differential Performance of P-tau217 in Reflecting Amyloid and Tau Stages in Cognitively Unimpaired and Impaired Individuals
Wednesday-352
The BEYONDD Project: Preliminary Findings within a Community-Based Sample
Wednesday-573
Associations between Digital Cognitive Assessment and Amyloid Burden in Cognitively Unimpaired Older Adults
*Work done at Dr. Bateman Lab, Washington University, St. Louis
We look forward to seeing you in Toronto!
About C2N Diagnostics, LLC
C2N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation™. C2N strives to provide exceptional laboratory services and products in the field of brain health. C2N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit www.C2N.com.